Highly active antiretroviral therapy (HAART) as risk factor for body fat distribution changes in HIV patients.

被引：0
|
作者：
Madeddu, G. [1 ,2 ]
Spanu, A. [2 ]
Chessa, F. [2 ]
Calia, G. M. [1 ]
Lovigu, C. [1 ]
Falchi, A.
Mannazzu, M. [1 ]
Solinas, P. [2 ]
Mura, M. S. [1 ]
Madeddu, G. [1 ,2 ]
机构：
[1] Univ Sassari, Dept Infect Dis, I-07100 Sassari, Italy
[2] Univ Sassari, Dept Nucl Med, I-07100 Sassari, Italy
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2007年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：S378 / S378
页数：1
相关论文
共 50 条
  • [1] Body fat loss and fat distribution changes in HIV patients treated with highly active antiretroviral therapy (HAART)
    Madeddu, G.
    Spanu, A.
    Chessa, F.
    Calia, G. M.
    Lovigu, C.
    Falchi, A.
    Mannazzu, M.
    Solinas, P.
    Mura, M. S.
    Madeddu, G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 : S411 - S411
  • [2] Body fat changes in HIV patients on highly active antiretroviral therapy (HAART): a longitudinal DEXA study
    Nuvoli, S.
    Caruana, G.
    Babudieri, S.
    Solinas, P.
    Pellicano, G.
    Piras, B.
    Fiore, V.
    Bagella, P.
    Calia, G. M.
    Yue, M.
    Spanu, A.
    Madeddu, G.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2018, 22 (06) : 1852 - 1859
  • [3] Body fat changes in HIV patients on highly active antiretroviral therapy (HAART): a longitudinal DEXA study
    Madeddu, G.
    Spanu, A.
    Solinas, P.
    Calia, G. M.
    Lovigu, C.
    Mannazzu, M.
    Bagella, P.
    Nuvoli, S.
    Mura, M. S.
    Madeddu, G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S803 - S803
  • [4] The efficacy of HAART (highly active antiretroviral therapy) in HIV positive tuberculosis (TB) patients.
    Jones, BE
    Otaya, M
    Hsu, V
    Rayos, E
    Louie, S
    Currier, J
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 159 (03) : A302 - A302
  • [5] Hepatotoxicity after introduction of highly active antiretroviral therapy (HAART) in HIV infected patients.
    Rodriguez-Rosado, R
    Garcia-Samaniego, J
    Perez-Olmeda, M
    Soriano, V
    Munoz, F
    Gonzalez-Lahoz, J
    HEPATOLOGY, 1998, 28 (04) : 434A - 434A
  • [6] Hepatotoxicity associated with highly active antiretroviral therapy (HAART) in HIV/AIDS patients
    Dragovic, G
    Jevtovic, D
    DRUG SAFETY, 2005, 28 (10) : 951 - 952
  • [7] Insomnia in HIV infected patients in the era of highly active antiretroviral therapy (HAART)
    LaRocco, A
    Scott, WR
    Aiken, M
    Rutledge, CM
    Green, GE
    Rivera-Tyler, T
    Ford, A
    Ware, CJ
    SLEEP, 2004, 27 : 339 - 339
  • [8] HIV, Highly Active Antiretroviral Therapy (HAART), Pancreatitis: Is There a Relationship?
    Beh, Y.
    Allan, S.
    DRUG SAFETY, 2012, 35 (10) : 887 - 888
  • [9] Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HAART)
    Dong, KL
    Bausserman, LL
    Flynn, MM
    Dickinson, BP
    Flanigan, TP
    Mileno, MD
    Tashima, KT
    Carpenter, CCJ
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 1999, 21 (02) : 107 - 113
  • [10] Body fat changes and lipodystrophy in HIV-infected children - Impact of highly active antiretroviral therapy
    Dzwonek, Agnieszka B.
    Lawson, Margaret S.
    Cole, Tim J.
    Novelli, Vas
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2006, 43 (01) : 121 - 123
12345